News
Comprehensive coverage on the latest pharmaceutical regulatory update and industry activities in China.
Hot topic
INDUSTRY
Are Cross-Border Licensing Deals a Shortcut to China's Pharma Market?
In 2021 H1, China has made 50 in-licensing deals, among which the top 10 add up to $5,197.5 million in value. Licensing deals do have advantages for promoting foreign drugs in China, but they are not shortcuts. Prudent work still needs to be done before making the deals.
Dec 07, 2021
POLICY
China's Insulin VBP Saw Average Price Cut of 48.75%
China’s insulin VBP (volume-based procurement)--eleven drug makers won the bid to supply insulin products to public healthcare institutions across China. Among 42 bid-winner products, Novo Nordisk took the champion with seven products. Two local Chinese companies—Gan & Lee and the United Laboratories—took the second and third places with six products respectively.
Dec 06, 2021
INDUSTRY
Marketing Approval
Priority Review and Approval
Innovative Drugs
Generic Drugs
Biological Products
Biosimilars
Drug Registration
New Drugs
Monthly Report: New Drug Approvals in China | Oct. 2021
In Oct. 2021, China's NMPA granted marketing authorization approvals to 11 new drugs, including Takeda's VOCINTI and Sanofi's Clopidogrel Bisulfate and Aspirin Tablets.
Nov 08, 2021
INDUSTRY
NMPA-Approved Injectable Fillers in China's Market
China’s promising injectable filler market is expected to witness other new products' emergence. The market size is predicted to grow from US$ 603.8 million in 2019 to US$ 1,063.53 million by 2026. Meanwhile, China tightens the regulation on aesthetic medical products or practices so injectable fillers and relevant businesses won’t be an exception.
Nov 04, 2021
INDUSTRY
Marketing Approval
Innovative Drugs
Generic Drugs
Biological Products
Biosimilars
Drug Registration
New Drugs
Monthly Report: New Drug Approvals in China | Sept. 2021
In Sept. 2021, China's NMPA granted 13 new drug approvals, including for Sanofi-Aventis Groupe's Dupilumab Injection and Merck's Pembrolizumab Injection.
Oct 25, 2021
REGULATION
Monthly Recap: China Pharmaceutical Regulatory Updates | June 2021
The monthly recap is intended to bring you the dynamics of recent major laws and regulations issued by China drug regulators, including National Medical Products Administration (NMPA) and the Center for Drug Evaluation (CDE).
Jul 20, 2021
Most Popular
- Online Conference | China Drug Regulation and Pharmaceutical Market
- China Cracks Down on Monopolies in Active Pharmaceutical Ingredient Industry
- Monthly Recap: China Pharmaceutical Regulatory Updates | Sept. 2021
- Monthly Report: New Drug Approvals in China | Sept. 2021
- China Chemical Drug Registration Classification
